Structure Therapeutics Business Summary

Structure Therapeutics Inc. (NASDAQ: GPCR) is a clinical-stage biopharmaceutical company that utilizes a proprietary structure-based drug discovery platform to develop oral small molecule therapeutics targeting G-protein coupled receptors (GPCRs). The company currently generates no product revenue, sustaining operations through equity financing—including a significant $747.5 million public offering in late 2025—and anticipates future revenue from potential licensing agreements, milestone payments, and the eventual commercialization of its metabolic and pulmonary pipelines. Its primary business segments are focused on metabolic diseases, led by its flagship oral GLP-1 receptor agonist aleniglipron (GSBR-1290) for obesity and type 2 diabetes, and pulmonary conditions such as idiopathic pulmonary fibrosis (IPF). Structure Therapeutics competes directly with industry titans Eli Lilly and Novo Nordisk, as well as clinical-stage peers Viking Therapeutics and Pfizer; it positions itself as a "second-wave" innovator aiming to disrupt the injectable-dominated incretin market with a highly scalable, oral alternative designed for superior gastrointestinal tolerability through biased GPCR signaling. The leadership team is anchored by Founder and CEO Raymond Stevens, Ph.D., a world-renowned pioneer in GPCR structural biology who previously co-founded Receptos and Syrrx. The executive suite includes Chief Financial Officer Jun Yoon, Chief Technology Officer Yingli Ma, Ph.D., and Chief Scientific Officer Xichen Lin, Ph.D. In late 2024, the company strategically bolstered its clinical operations by promoting Blai Coll, M.D., Ph.D. (formerly of Amgen and AbbVie) to Chief Medical Officer and appointing Ashley Hall, J.D. (formerly of Reneo and Esperion) as Chief Development Officer to oversee the transition of aleniglipron into Phase 3 global trials. The company is backed by a high-pedigree board including Angus C. Russell (former CEO of Shire) and Ramy Farid, Ph.D. (CEO of Schrödinger), with a robust institutional investor base featuring Fidelity (FMR LLC), Wellington Management, and Avoro Capital Advisors.